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Abstract
The ubiquitin-proteasome system (UPS) degrades soluble proteins and small aggregates,
whereas macroautophagy (autophagy herein) eliminates larger protein aggregates, tangles
and even whole organelles in a lysosome-dependent manner. VCP/p97 was implicated in
both pathways. VCP/p97 mutations cause a rare multisystem disease called IBMPFD
(Inclusion Body Myopathy with Paget’s Disease and Frontotemporal Dementia). Here, we
studied the role IBMPFD-related mutants of VCP/p97 in autophagy. In contrast with the
wild-type VCP/p97 protein or R155C or R191Q mutants, the P137L mutant was aggregate-
prone. We showed that, unlike commonly studied R155C or R191Q mutants, the P137L
mutant protein stimulated both autophagosome and autolysosome formation. Moreover,
P137L mutant protein itself was a substrate of autophagy. Starvation- and mTOR inhibi-
tion-induced autophagy led to the degradation of the P137L mutant protein, while preserv-
ing the wild-type and functional VCP/p97. Strikingly, similar to the P137L mutant, other
IBMPFD-related VCP/p97 mutants, namely R93C and G157R mutants induced autophago-
some and autolysosome formation; and G157R mutant formed aggregates that could be
cleared by autophagy. Therefore, cellular phenotypes caused by P137L mutant expression
were not isolated observations, and some other IBMPFD disease-related VCP/p97 muta-
tions could lead to similar outcomes. Our results indicate that cellular mechanisms leading
to IBMPFD disease may be various, and underline the importance of studying different dis-
ease-associated mutations in order to better understand human pathologies and tailor
mutation-specific treatment strategies.
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Introduction
Inclusion bodymyopathy with early-onset Paget’s disease and frontotemporal dementia
(IBMPFD) is a rare hereditary disorder with multisystem involvement. The disease has an
autosomal dominant inheritance, yet it shows adult-onset (Age 20 to 40 years). Myopathy
observed in IBMPFD patients may result in disablingmuscle weakness, which might eventually
be life-threatening due to cardiac and respiratory muscle involvement. Paget’s disease is the
cause of bone pain and fractures in the hips, the spine, the skull and in the long bones of arms
and legs. In 30% of patients, brain involvement might be manifested as frontotemporal demen-
tia, leading to learning and memory deficits, speech problems, personality changes and defects
in social skills. Currently, there is no cure for IBMPFD. The only treatment modality that can
be offered to patients is palliative, aiming to alleviate disease symptoms.
The IBMPFD disease locus was mapped to the chromosome 9p21.1-p12 and the disease was
associated with mutations of the VCP/p97 gene. Among disease-causingmutations, arginine
155 (R155) mutation was reported to be the most common one [1–3]. Patients carryingR155C
mutations as well as those with R191Qmutations manifested all above-mentioned symptoms
of the IBMPFD disease [4–7]. On the other hand, P137L was observed in a Finnish family and
the disease affected nine members during 3 generations. In addition to distal leg muscle weak-
ness and atrophy in the anterior compartment muscles, rapidly progressive demetia was
observed in this family [8].
VCP/p97 is an essential protein that was conserved from archaea to man (Ter94 in D. mela-
nogaster and CDC48 in S. cerevisiae). The protein is a member of the ATPase associated with
various cellular activities (AAA) protein family, and it is one of the most abundant cytosolic
proteins. Biological processes involving VCP/p97 include, endoplasmic reticulum-associated
degradation (ERAD) pathway, nuclear envelope reconstruction, post mitotic Golgi reassembly
and apoptosis [1, 5, 9, 10].
Cytoplasmic aggregates in the affected tissues (brain, bone, muscle) of IBMPFD patients
were found to be positive for VCP/p97 and ubiquitin, suggesting that defects in protein degra-
dation pathways might contribute to the pathogenesis and progression of the disease [5, 9–11].
Indeed, mutant VCP/p97 proteins were shown to cause ERAD defects [12–20]. Expression of
the IBMPFD disease-associatedVCP/p97 mutants R155 and A232 in cells or in mice stimu-
lated autophagic vesicle accumulation [21]. These mutants were reported to cause abnormali-
ties of autophagosome maturation as well, i.e. causing defects of autophagosome-lysosome
fusion and autolysosome generation [21, 22]. Moreover, autophagic markers were accumulated
in the affected tissues of the VCP/p97 mutant mice [22].
Autophagy is an evolutionarily conserved catabolic process that is responsible for the degra-
dation of cytosolic components, including damaged organelles, protein clumps and aggregates
which cannot be degraded by the UPS [23, 24]. Indeed, protein aggregates were observed in
various tissues, including brain, bone and muscle of autophagy-defectivemice [14, 25]. Pro-
teins and organelles targeted for autophagic destruction are sequestered in double-membrane
vesicles called "autophagosomes", that in turn fuse with lysosomes to give rise to "autolyso-
somes". Lysosomal enzymes, e.g. proteases or lipases, degrade autophagy cargos into their
building blocks (e.g. proteins to amino acids) within the acidic environment of autolysosomes.
Building blocks are then transported back to cytosol for reuse by the cell, allowing recycling of
cellular material.
Around 30 autophagy proteins (ATG proteins) are involved in autophagic vesicle formation
and maturation. Autophagic membrane elongation and vesicle completion requires ATG8/
MAP1LC3 (shortly LC3) proteins. LC3 processing at the C-terminus by ATG4 creates the free
cytosolic LC3-I form of the protein. Upon activation of autophagy pathways, two
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ubiquitylation-likemechanisms catalyze conjugation of LC3-I to a lipid molecule, a phosphati-
dylethanolamine (PE), and form the autophagic membrane-associated LC3-II form [26, 27].
Lipidation of LC3 result in a change in its molecular weight from 18 kDa (LC3-I) to16 kDa
(LC3-II), and detection of a shift in SDS-PAGE gels is one of the most commonly used tests of
autophagy detection. A green fluorescent protein-fused form of LC3 (GFP-LC3) is also widely
used to detect autophagy. In this test, recruitment of cytoplasmic diffuseGFP-LC3 protein to
autophagosomes results in the formation of GFP-LC3-labeled punctuate structures, allowing
quantification of autophagy using fluorescencemicroscopy [26]. Mitophagy is a special type of
autophagy during which old/damagedmitochondria are first ubiquitylated by E3-ligases such
as PARK2 (Parkin), and then degraded by the autophagy machinery. Several recent studies
point out to the involvement of VCP/p97 in mitophagy [28, 29].
In this study, we identifiedVCP/p97 P137L mutant proteins as autophagy targets. We con-
firmed that mere expression of the VCP/p97 P137L mutant was sufficient to induce autophagy
under basal fed conditions. In contrast with previous reports using commonly studiedmutants
(R155 or A232), P137L mutant did not cause an autophagosome maturation defect, and it did
not prominently influence autophagic vesicle fusion with lysosomes. Strikingly, autophagy acti-
vation by starvation led to a lysosomal activity-dependent preferential degradation of the
P137L mutant while sparing the wild-typeVCP/p97 protein. Autophagy inducer and mTOR
inhibitor Torin-1 showed similar effects. P137L mutant was not an isolated case:We demon-
strated that another IBMPFD disease-relatedmutant, the G157Rmutant formed aggregates,
induced productive autophagy and it was cleared by autophagic degradation. Our results
showed that, in contrast with the current litterature, some VCP/p97mutants are targets of
autophagic degradation. Additionally they underline the fact that, even though they all lead to
the same disease, different IBMPFD-related VCP/p97 mutations may have different functional
outcomes at a molecular and cellular level.
Materials and Methods
Plasmids and constructs
VCP/p97 mutants were created using site-directedmutagenesis through mutation of the wild-
type VCP/p97 constructs in the pCDNA3-VCP/p97-myc vector as previously described [17].
GFP-LC3 and GFP and RFP tandemly tagged LC3 (tfLC3 or RFP-GFP-LC3) and LAMP1 con-
structs were also described [7, 26, 30]. pMX-puro-GFP-p62 plasmid (plasmid number: 38277)
was reposited from Addgene [31].
Cell Culture and transfection
Human embryonic kidney (HEK293T) and human osteosarcoma (U2OS) cells were cultured
in DMEM (Dulbecco’s modifiedEagle’s medium; Biological Industries, Cat. No: BI01-050-1A)
supplemented with 10% (v/v) fetal bovine serum (FBS; PAN, Cat. No: P30-3302), antibiotics
(penicillin/streptomycin; Biological Industries, Cat. No: 03-031-1B) and 1% (2 mM) L-gluta-
mine (Biological Industries, Cat. No: 03-020-1B). Rat adrenal gland pheochromocytoma (PC-
12) cell line was cultured in Ham's F-12K (Kaighn's) Medium (HyClone/Thermo, Cat. No:
HY-SH30526.01) supplemented with 17.5% (v/v) fetal bovine serum (FBS; PAN, Cat. No: P30-
3302), antibiotics (penicillin/streptomycin; Biological Industries, Cat. No: 03-031-1B) and 1%
(2 mM) L-glutamine (Biological Industries, Cat. No: 03-020-1B). All cell lines were cultured
under 5% CO2 in a 37°C humidified incubator. Transient transfections were performed using
standard calcium-phosphate precipitation method. U2OS stable polyclones were generated fol-
lowing selection of transfected cells with 50 μg/ml G418 for 4 weeks.
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Starvation-induced autophagy was achieved by incubating cells in EBSS (Earle’s Balanced
Salt Solution, Biological Industries, Cat. No: 02-010-1A) for indicated times. Autophagy activa-
tion was also activated by incubating cells for 3 hours in a full cell culture medium supple-
mented with 250 nM Torin-1 (Tocris, Cat. No: 4247). For inhibition of lysosomal activity, cells
are treated with 10 μM of E64d (Santa Cruz, Cat. No: Sc201280A) and 10 μM pepstatin A
(Sigma, Cat. No: P5318) for 4 hours or 10 μM of cloroquine (Sigma, Cat. No: C6628) for 40
min. 1 μg/ml Tunicamycin (Sigma, Cat. No: T7765) was used as a ER-stress inducer for 1,2,4
and 8 hours. 1μM Cycloheximide (Sigma, Cat. No: C1988) was used to inhibit protein synthesis.
Primary myoblast cell isolation and culture
Primarymyoblast isolation protocol was adapted from Springer et al. [32]. Briefly, C57B6 male
mice were sacrificed, limb and pectoralmuscles were removed and diced in DMEM. For 1 ml
medium, 500 μl Liberase enzyme (Liberase TL Research Grade, Roche Cat. No: 05401020001.
2,5 mg/ml stock) was added and tissues were incubated at 37°C degree for 90 min under rota-
tion. Following 3 washes in DMEM plus 5% FBS, myoblasts were cultured in DMEM supple-
mented with 10% (v/v) fetal bovine serum (FBS; PAN, Cat. No: P30-3302), antibiotics
(penicillin/streptomycin; Biological Industries, Cat. No: 03-031-1B) and 1% (2 mM) L-gluta-
mine (Biological Industries, Cat. No: 03-020-1B).
Immunoprecipitation and Immunoblotting
For immunoprecipitation, cells were transfected in 10 cm plates (2 x 106 cells/plate) cultured
for 48 hours. After transfection, cells were washed 3 times with cold PBS by centrifugation
(13200 rpm, 5min, 4°C). The resulting pellet was resuspended in cold RIPA buffer (1M Tris-
HCl, pH 7.6, 5% deoxycholic acid, 10% NP-40, and 0.5 M NaCl) supplied with protease inhibi-
tior cocktail (Sigma, Cat. No: P8340) and 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma-
Aldrich, P7626). Cell lysate was cleared by centrifugation at 13200 rpm for 15 min at 4°C and
protein concentrations were estimated by using the Bradford Reagent (Sigma Aldrich, Cat. No:
B9616). 1mg of protein was loaded onto the Myc-beads (Sigma-Aldrich, Cat. No: A7470).
After several washing with cold PBS and RIPA buffer, the samples were incubated for over-
night at 4°C on a rotator. In order to remove non-specific binding, the samples were washed 3
times with RIPA and then analyzed by SDS-PAGE. Immunoblotting was performed as previ-
ously described [33]. Briefly, 30 μg of protein was loaded into 15% SDS polyacrylamide gels.
Following transfer, nitrocellulosemembranes (Millipore, Cat. No: IPVH00010) were blocked
with 5% nonfat milk in PBST (3.2 mMNa2HPO4, 0.5 mMKH2PO4, 1.3 mMKCl, 135 mMNaCl
and 0.05% Tween 20, pH 7.4) for 1 h and then incubated with 3% BSA containing PBST solu-
tion with primary antibodies: Anti-myc (Origene, Cat. No: TA100010), anti-LC3B (Novus,
2331), anti-VCP/p97 (BD Transduction Laboratories, Cat. No: 612183), anti-GFP (Roche, Cat.
No: 11814460001), anti-ubiquitin (Cell Signaling Technology, Cat. No: P4D1) (Santa Cruz,
Cat. No: sc8017) antibodies were used. Anti-β-ACTIN (Sigma-Aldrich, Cat. No: A5441) anti-
body was used as loading control. Anti-mouse (Cat. No: 115035003) and anti-rabbit (Cat. No:
111035144) secondary antibodies were purchased from Jackson Laboratories. ImageJ software
was used for band intensity quantification [34].
GFP-LC3 and RFP-GFP-LC3 autophagy analyses
Cytoplasmic puncta formation by otherwise soluble GFP-fused LC3 protein is used as a
method to quantify autophagy activation under a fluorescencemicroscope [26]. Briefly, cells
were cultured on top of poly-L-Lys coated coverslides. 48 hours after transfection, cells were
fixed with ice-cold 4% PFA in PBS for 30 min. GFP-LC3 dot analysis was performed.
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Coverslides were analyzed under fluorescencemicroscope (Olympus BX60, Japan) under 60x
magnification.Minimum 150 cells per condition were analyzed. Cells containing more than 15
dots were considered as autophagy positive. Percentage of GFP- LC3 positivity was expressed
as a percentage of GFP-LC3 dot positive cells within the total transfected cell population.
RFP-GFP-LC3 dot numbers were determined under a fluorescencemicroscope (Olympus
BX60, Japan) using 60x magnification. Dot numbers were analyzed in 50 cells for each experi-
mental point. Autophagosomes gave both RFP and GFP signals, while autolysosomes were
defined as RFP positive dots. Number of autolysosomes was calculated by subtractingGFP pos-
itive dot numbers from RFP positive dot numbers.
Immunofluorescence and confocal microscopy analyses
Cells were seeded in 12-well plates (50,000 cells/well) in poly-L-Lysine (Sigma, Cat. No: P8920)
coated coverslides. 48 hours after transfection, cells were fixed in 4% PFA for 30 min, washed
with PBS and permeabilizedusing 0.1% Saponin and 0.1% BSA in PBS. After PBS washes, cov-
erslides were incubated with the primary antibody for 1h at RT. Then, coverslides were incu-
bated with Alexa594-(Molecular probes, Cat. No: 927075) or Alexa488-(Molecular probes, Cat.
No: 948490) conjugated secondary antibodies for 1h at RT. Coverslides were mounted using
50% glycerol in 1X PBS at RT. Pictures were taken using the Zen software (Carl-Zeiss, Ger-
many). Intracellular localizations of proteins were analyzed under a fluorescent microscope
(Olympus BX60, Japan) and/or using confocal microscopy (Carl-Zeiss LSM 710, Germany).
Objective lens of confocal microscope is plan-apochromat, 63x/1.40 Oil DIC M27. Objective
lens of flourescentmicroscope is plan-apochromat 60x/1.42 Oil.
Cell Fractionation
To separate cell lysate into soluble and insoluble fractions, cells were lysed in Triton X-100 lysis
buffer on ice for 30 min, then centrifuged at 14,000 rpm for 10 min. The resulting pellet was
lysed in the SDS lysis buffer as the insoluble fraction. The supernatant was used as the soluble
fraction.
Statistical analyses
Statistical analyses were performed using Student’s two tailed t-test. Data were represented as
means of ±S.D. of 3 independent experiments. Values with p< 0.05 were considered as
significant.
Results
Various mutants of VCP/p97 were associated with the IBMPFD disease.Majority of reported
mutations were shown to affect the N-terminal cofactor-binding domain of the VCP/p97 pro-
tein, but other mutations involving ATPase domains and linker regions were observed as well
(Fig 1A). We screened the effect of expression of a number of IBMPFD-causingmutants of
VCP/p97 on autophagy, and discovered that most mutants stimulated autophagy-associated
LC3-II formation. Among them, P137L mutant VCP/p97 was one of the strongest inducers of
autophagy in our analyses. In contrast with R155, A232 and R191 mutants of VCP/p97, the
P137 mutant was shown to be defective in binding co-factors Npl4, Ufd1 and p47, components
necessary for proper functioning of the protein in pathways including ERAD [17].
Indeed, expression of the P137L mutant protein resulted in a prominent LC3 shift and
autophagy-associated LC3-II formation compared to wild-type (WT) VCP/p97 (Fig 1B). To
further validate these results, GFP-LC3 dot formation was used as another autophagy test.
P137L and G157C Mutant VCP/p97 Proteins Are Autophagy Targets
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Overexpression of P137L mutant protein led to a strong and significant increase in autophagic
GFP-LC3 dot formation in cells expressing P137 mutant VCP/p97 compared to controls (Fig
1C and 1D). All these results showed that the P137L mutant is a potent activator of autophagy.
Commonly studied IBMPFD-related mutants of VCP/p97 R155C, R155H and A232E, were
shown to interfere with autophagic vesicle maturation and lysosomal fusion, leading to the
accumulation of autophagic vesicles and to the perturbation of the autophagic flux [21, 22]. To
study a possible effect of the P137L mutant on autophagosome-autolysosome fusion, we used
RFP-GFP-LC3 fusion protein as a marker. Here, GFP and RFP both mark autophagosomes.
But following fusion with lysosomes, the GFP part is quenched in the acidic environment,
while the RFP still emits fluorescence,marking the autolysosomal compartment. Using this
method, autophagosome-autolysosome numbers can readily be calculated [7]. RFP-GFP-LC3
analyses showed that both autophagosome (green) and autolysosome (red minus green) num-
bers were increased upon P137L mutant overexpression in HEK293T cells (Fig 2A). The
increase in autophagosome and most strikingly autolysosome numbers were significantly
higher in cells overexpressing the P137L mutant, compared to negative control and WTVCP/
p97 (Fig 2B). Of note, while both proteins were expressed in comparable amounts, the increase
in autolysosome numbers was almost double in P137L mutant expressing cells compared to
cells with theWT VCP/p97 (Fig 2B). Moreover, autophagic LC3-II levels were markedly
increased in P137L expressing cells upon inhibition of lysosomal proteases using E64d and
Fig 1. VCP/p97 mutant P137L induced autophagy. (A) Primary structure of VCP/p97 protein and IBMPFD-related
mutations. Major protein domains were shown. Bold, P137 mutant; underlined, R155, R191 and A232 mutants. (B)
HEK293T cells were transfected with empty vector (CNT), MYC-tagged wild type (WT) or mutant VCP/p97 (P137L)
and western blot analysis was performed using MYC, LC3 and ACTIN antibodies. ACTIN was used as loading control.
LC3-I and LC3-II band intensity was quantified on scans of immunoblot films using Image J software. LC3-II/LC3-I
ratios were determined after subtraction of non-band containing area intensities, and normalized to CNT condition. (C
and D) WT or P137L mutant VCP/p97 were co-transfected with GFP-tagged LC3 in HEK293T cells and dot formation
was visualized (C) and quantified (D). Data were shown as mean ± SD of independent experiments (n = 3) *** p<0.01.
doi:10.1371/journal.pone.0164864.g001
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Pepstatin A. During autophagy, LC3-II itself is delivered to autolysosomes and it is normally
degraded in this compartment through the action of lysosomal hydrolases. Therefore, accumu-
lation of LC3-II upon lysosomal protease inhibition indicated that autophagosome maturation
and autolysosomal activity were intact (Fig 2C). Similar results were also obtained in U2OS
(Fig 3A and 3B) and PC-12 cells (Fig 3C and 3D). Suprisingly, R155Cmutant did also induce a
significant amount of autolysosome formation in the U2OS cell line. Moreover, following treat-
ment of the same cell types with chloroquine (a lysosomotropic agent that prevents lysosomal
acidification and autophagosome-lysosome fusion), mutant proteins led to further accumula-
tion of autophagosomes, indicating that the dominant effect of mutant proteins indeedwas
stimulation of autophagy rather than blockage of autophagosome-lysosome fusion (S1A–S1D
Fig). These results showed that, the P137L mutant did not have a prominent effect on autopha-
gosomematuration and autolysosome formation in HEK293T cells, and more importantly in
IBMPFD disease-relevant U2OS bone-derived cells and PC-12 neuronal cells.
While analyzing intracellular localization of VCP/p97 mutants, we realized that, in contrast
with theWTVCP/p97 and commonly tested R155Cmutant showing a rather diffuse cyto-
plasmic pattern, the P137L mutant was localized to punctate structures in the cytosol (S2A Fig
and see the reference [17]). This punctuate pattern of the P137L mutant was also observed in
primarymyoblast cells in culture (S2B Fig). Additionally, while theWTVCP/p97 protein was
mostly found in the soluble fraction of cells, a major fraction of the P137L mutant protein was
insoluble in HEK293T (S2C Fig), U2OS (S2D Fig) and PC-12 (S2E Fig) cells. Moreover, these
Fig 2. VCP/p97 P137L mutant induced both autophagosome and autolysosome formation in HEK293T cells. (A) Cells expressing
empty vector (CNT), wild type (WT) or mutant VCP/p97 (P137L) were co-transfected with RFP-GFP-LC3 fusion construct and dot formation
was visualized under fluorescent microscope. Arrow heads indicate autophagosomes and arrows indicate autolysosomes. (B) The graph
shows the number of autophagosomes and autolysosomes in WT and P137L mutant expressing cells. Data were shown as mean ± SD of
independent experiments (n = 3). **, p<0.05; ***, p<0.01 (C) Cells were transfected with CNT, and MYC-tagged WT or P137L mutant in the
absence or presence of lysosomal inhibitors E64d and Pepstatin A (PepA) and western blot analysis was performed. ACTIN was used as
loading control. ImageJ software was used for the quantification of band intensities.
doi:10.1371/journal.pone.0164864.g002
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aggregates were found to colocalizewith the autophagy adapter/receptor p62 under basal and
starved conditions (S2F Fig).
To determine the intracellular localization of P137L punctuate structures, we performed
confocal microscopy analyses. We observed that P137L partially colocalizedwith the GFP-LC3
autophagic vesicle marker under basal/non-starvedconditions in HEK293T (Fig 4A), U2OS
(Fig 4D) and PC-12 cells (Fig 4G). Importantly, upon induction of autophagy by starvation,
the overlap between LC3 and P137L mutant puncta significantly increased in all tested cell
types (Fig 4B, 4C, 4E, 4F, 4H and 4I). In these studies, WT VCP/p97 was used as a control and
showed minimal colocalizationwith the autophagy marker LC3 (Fig 4A–4I).
LAMP1 is an integral membrane protein of autolysosomes. Confocal analyses using
LAMP1 as an autolysosome marker showed that whileWTVCP/p97 protein overexpression
resulted in a minimal colocalization, P137L mutant VCP/p97 partially colocalizedwith autoly-
sosomes under non-starved conditions in HEK293T (Fig 5A and 5C), U2OS (Fig 5D and 5F)
and PC-12 cells (Fig 5G and 5I). Strikingly, P137L colocalizationwith LAMP1 was significantly
increased following autophagy induction by starvationin the tested cell lines (Fig 5B, 5C, 5E,
5F, 5H and 5I).
Results obtained so far showed that P137L mutant VCP/p97 could be a target of autophagic
degradation. To test this hypothesis, we overexpressedWTVCP/p97 or the P137L mutant in
cells, and analyzed the effect of autophagy activation on VCP/p97 protein levels. Upon minutes
of starvation, the amount of P137L mutant protein gradually decreased in HEK293T cell
extracts, but WTVCP/p97 protein levels remained relatively stable (Fig 6A). To further
Fig 3. VCP/p97 P137L mutant induced both autophagosome and autolysosome formation in U2OS
and PC-12 cells. (A and C) Cells expressing wild type (WT), mutant(P137L or R155C) VCP/p97 were co-
transfected with RFP-GFP-LC3 fusion construct and dot formation was visualized in U2OS (A) and PC-12
(C) cells. Arrow heads indicate autophagosomes whereas arrows indicate autolysosomes. (A and C) The
graphs show the number of autophagosomes and autolysosomes in U2OS (B) and PC-12 (D) cells. Data
were shown as mean ± SD of independent experiments (n = 3). * p<0.05, ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0164864.g003
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confirm that autophagic protein degradation was responsible for the observeddecrease in P137
protein levels, we performed starvation experiments in the absence or presence of lysosomal
inhibitors. Addition of lysosomal protease inhibitors E64d/PepstatinA reversed the effect of
starvation on P137L protein levels, and resulted in its accumulation, whileWTVCP/p97 levels
were relatively stable (Fig 6B). Another lysosomal inhibitor chloroquine, gave similar results
confirming that P137L degradation was dependent on lysosomal activity (Fig 6C). A decrease
in P137L mutant protein levels upon starvation, and a lysosome-inhibition-dependent accu-
mulation of the mutant protein were also observed in U2OS cells (Fig 6D).
To test whether VCP/p97 mutants R155C and R191Q were degraded by autophagy, mutant
proteins were overexpressed in cells, and starvation assays were performed in the presence or
absence of the lysosomal inhibitor chloroquine. Different from the P137L mutant, VCP/p97
mutants R155C and R191Q were not degraded upon autophagy activation by starvation, and
consequently, inhibition of the autolysosomal activity by chloroquine did not result in their
accumulation in either HEK293T (Fig 6E) or U2OS (Fig 6F) cells.
In addition to starvation, various agents and chemicals were shown to induce autophagy.
Torin-1 is a specific inhibitor of the mTOR kinase and a classical inducer of autophagy. There-
fore, we tested the effect of autophagy-induction by this compound on P137L mutant protein
levels. As shown in Fig 6G, Torin-1 was able to stimulate LC3-II formation and activate autop-
hagy under our experimental conditions. In line with starvation assays, following Torin-1 treat-
ment, P137L mutant protein levels were decreased upon autophagy activation, whileWT
Fig 4. Mutant VCP/p97 colocalized with the autophagic vesicle marker LC3 during starvation. HEK293T (A-C), U2OS (D-F)
and PC-12 (G-I) cells expressing wild type (WT) or mutant VCP/p97 (P137L) were co-transfected with GFP-LC3 and colocalization
was analyzed by confocal microscopy under basal/non-starved (NON-STV) (A, D, G) or starved (STV) (B, E, H) conditions.
Overexpressed MYC-VCP was indirectly immunostained using anti-MYC antibodies. Arrowheads indicate colocalized dots in (A,
B),(D,E) and (G,H). Quantification of co-localized dots in HEK293T (C), U2OS (F) and PC-12 (I) cells. Minimum 40 cells were
counted under each condition, and quantification was expressed as a percentage of colocalization positive cells within a total
transfected cell population. Data were shown as mean ± SD of independent experiments (n = 3). * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0164864.g004
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VCP/p97 levels and R155Cmutant levels remained constant (Fig 6H). Moreover, inhibition of
the lysosomal activity in Torin-1-stimulated cells by chloroquine, blocked P137L mutant pro-
tein degradation and led to its accumulation.
To exclude the possibility that P137L mutant VCP/p97 is a short-lived protein that is prone
to degradation in cells following expression, we treated cells with cycloheximide, a protein syn-
thesis inhibitor, and comparedWT and P137L mutant VCP/p97 protein levels, and observed
no obvious difference in stability (S3 Fig). Therefore, P137L mutant protein was a target of
autophagy and autolysosomal degradation, whileWT VCP/p97 or other relatively soluble
mutants of VCP/p97 were not.
VCP/p97 proteins work as homo-hexamers.We wondered whether P137L mutant VCP/p97
could still interact with its WT counterpart and lead to the perturbation of its function. To
address this question, we co-expressedwild-type and mutant VCP with different tags (GFP-
taggedWTVCP/p97 and MYC-tagged P137L) in cells, and checked whether they interacted.
Immunoprecipitation experiments showed that, P137L mutant could still bind toWTVCP/p97
(S4 Fig) and possibly took part in VCP/p97 hexamers to a certain extent. Since theWTVCP
was minimally degraded following induction of autophagy (Fig 6), our data indicate that most
P137L mutant aggregates did not includeWT proteins. In a previous work, we showed that the
P137L mutant VCP/p97 was unable to bind its ERAD-related co-factors, and it interfered with
the ERAD-mediated degradation of CFTRΔF508 and Tyrosinase C89Rmutant proteins [17]. In
line with this, expression of the P137L mutant VCP/p97 resulted in the accumulation of
Fig 5. Mutant VCP/p97 colocalized with the lysosome/autolysosome marker LAMP1 during starvation. HEK293T (A-C),
U2OS (D-F) and PC-12 (G-I) cells expressing wild type (WT) or mutant VCP/p97 (P137L) were co-transfected with LAMP1-RFP and
colocalization was analyzed by confocal microscopy under basal/non-starved (NON-STV) (A, D, G) or starved (STV) (B, E, H)
conditions. Overexpressed MYC-VCP was indirectly immunostained using anti-MYC antibodies. Arrowheads indicate colocalized
dots in (A,B),(D,E) and (G,H). Quantification of co-localized dots in HEK293T (C), U2OS (F) and PC-12 (I) cells. Minimum 40 cells
were analyzed under each condition, and quantification was expressed as a percentage of colocalized positive cells within the total
transfected cell population. Data were shown as mean ± SD of independent experiments (n = 3). * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0164864.g005
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ubiquitylated proteins in cells treated with ER stress inducer tunicamycin (S5 Fig). Therefore,
non-functionalWT/mutant hetero-hexameric VCP complexes, mutant protein insoluble aggre-
gates as well as possible saturation of the UPS by misfoldedmutant and endogenous proteins
could be in the origin of cellular defects observed in IBMPFD diseased cells.
To determine whether the P137L mutant is the only VCP/p97 mutant that led to above-
mentioned cellular outcomes, we also checked the effects of two other mutant proteins, namely
VCP/p97 R93C and G157Rmutants. Patients with R93Cmutation as well as those with G157R
mutation manifested all cardinal signs and symptoms of the disease, including muscle
Fig 6. P137L mutant VCP/p97, but not the WT VCP/p97 or R155C and R191Q mutants, was a target of starvation-
induced autophagy. (A) HEK293T cells were transfected with empty vector (CNT), MYC-tagged wild type (WT) or mutant
VCP/p97 (P137L) and then starved for indicated time points. (B and C) HEK293T cells and (D) U2OS cells expressing empty
vector (CNT), wild type (WT) or mutant (P137L) VCP/p97 were starved for 40 min in the absence or presence of lysosomal
inhibitors E64d/Pepstatin A (E64D/PEPA) or chloroquine (CQ). (E) HEK293T cells and (F) U2OS cells expressing other VCP/
p97 mutants (R155C) and (R191Q) were starved for 40 min in the absence or presence of lysosomal inhibitor chloroquine (CQ).
(G) U2OS cells expressing wild type (WT) or mutant VCP/p97 (P137L) and (R155C) were starved for 40 min in the absence or
presence of lysosomal inhibitor chloroquine (CQ). (H) U2OS cells were treated with carrier (DMSO) or Torin-1 (TRN) and
western blot analysis was performed by using LC3 antibody. (I) Cells were transfected with wild type (WT) and mutant (P137L
or R155C) VCP/p97 and treated with TRN in the presence or absence of CQ. ACTIN was used as loading control. Image J
software was used for the quantification of band intensities. Western blot analysis was performed by using MYC and ACTIN
antibodies. ACTIN was used as loading control. Image J software was used for the quantification of band intensities.
doi:10.1371/journal.pone.0164864.g006
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weakness, Paget’s disease of bone and cognitive decline [35]. In addition to these symptoms,
two patients with the G157Rmutation had early hearing impairment, a symptom that is
uncommon to IBMPFD patients [5, 35]. Both R93C and G157Rmutant proteins, were able to
bind cofactors Npl4 and Ufd1 [17]. But only the G157R mutant was able to strongly induce
autophagy as the P137L mutant did (Fig 7A–7C). Similar to observationswith the P137L
mutant, expression of the G157Rmutant, but not the R93Cmutant, led to a robust accumula-
tion of both autophagosomes and autolysosomes (Fig 7D and 7E). Last but not least, starvation
caused complete degradation of G157Rmutant in a lysosomal activity-dependentmanner (Fig
7F), while the R93Cmutant protein levels were not affected under these conditions. Yet,
G157R as well as R93C were found in both the soluble and the insoluble fraction of cells, the
amount of insoluble G157R aggregates beingmore prominent (Fig 7G and 7H). Aggregation of
the R93Cmutant to a certain extent but lack of its degradation by autophagy might be the
result of an autophagy defect caused by this mutant.
Discussion
In this study, we showed that an IBMPFD-associatedmutant VCP/p97 form, the P137L
mutant protein is a target of macroautophagic degradation.We demonstrated that expression
of the P137L mutant protein led to LC3 gel shift and GFP-LC3 dot formation under both basal
and starvation conditions, highly indicative of autophagy activation. Moreover, in contrast
with previous reports using other IBMPFD-related VCP/p97 mutants (R155 and R191), the
P137L mutant did not interfere with autophagosome-lysosome fusion and autolysosomal func-
tion, shown here as follows: i.RFP-GFP-LC3 analyses showed a significant increase in both
autophagosome and autolysosome numbers; ii.VCP/p97 P137L mutant protein formed cyto-
solic insoluble aggregates that colocalizedwith the autophagy marker GFP-LC3 and lysosomal
protein LAMP1; iii. Addition of lysosomal inhibitors resulted in the accumulation of both
LC3-II and mutant VCP/p97 under conditions activating autophagy (i.e. starvation and Torin-
1 treatment). All these results showed that P137L mutant protein did not affect autophagosome
maturation or lysosomal activity. Strikingly, P137L mutant protein formed aggregates that
colocalizedwith the autophagy receptor p62 and that were targeted by autophagy and degraded
by the autolysosomal activity. We also showed that another VCP/p97 mutant, G157R also
formed aggregates that could be cleared by autophagy, underlining the fact that cellular pheno-
types caused by P137L mutant expression were not isolated observations, and some other
IBMPFD disease-relatedmutations might lead to similar outcomes.
IBMPFD is rare disease with an autosomal dominant inheritance and individuals from
around 100 families were reported to suffer from the disease.Most common VCP/p97 muta-
tions causing IBMPFD disease involved the R155 residue (around half of the reported cases).
Consequently, almost all molecular studies were conducted using cells or animals expressing
R155 mutant proteins as IBMPFD disease experimentalmodels.We showed that, the P137L
mutant VCP/p97 protein that was reported to cause IBMPFD diseasebehaved in a different way
than the commonly studiedmutant R155 [36][8]. In contrast with other VCP/p97 mutants,
P137L mutant did not bind ERAD-related co-factors, and formed insoluble protein aggregates.
Moreover, expression of the P137L mutant did not result in autophagosome maturation defects
that were reported to be associated withthe VCP/p97 R155 mutant [21, 22]. In contrast, P137L
protein aggregates colocalizedwith autophagosome and autolysosome markers, and they were
degraded in autolysosomes, whileWT and healthy VCP/p97 protein levels were maintained.
We confirmed in our experimental system that R155C and R191Qmutants did not share the
same faith with the P137L mutant. Strikingly, activation of autophagy was previously reported
to aggravate the pathology in an R155Cmutant mice model of the disease [37].
P137L and G157C Mutant VCP/p97 Proteins Are Autophagy Targets
PLOS ONE | DOI:10.1371/journal.pone.0164864 October 21, 2016 12 / 19
Fig 7. Another IBMPFD disease-associated mutant, the G157R mutant, was an autophagy target. (A-C) WT or mutant VCP/
p97 constructs were co-transfected to HEK293T cells with GFP-tagged LC3 and autophagosomal dot formation was visualized (A)
and quantified (B). Data were shown as mean ± SD of independent experiments (n = 3) ** p<0.01, *** p<0.001. (C) Example of
an immunoblot showing the expression of WT or mutant VCP/p97 proteins in A and B. (D) HEK293T cells expressing VCP/p97
R93C or G157R mutants were co-transfected with RFP-GFP-LC3 fusion construct and dot formation was visualized under
fluorescent microscope. Arrow heads indicate autophagosomes (yellow) and arrows indicate autolysosomes (red). (E)
Quantification of autophagosome (APG) and autolysosome (ALY) numbers in cells expressing R93C or G157R mutants. Data
were shown as mean ± SD of independent experiments (n = 3). *, p<0.05; ***, p<0.01 (F) Cells were transfected with MYC-
tagged R93C or G157R mutant VCP/p97 constructs and starved (STV) or not in the absence or presence of the lysosomal
inhibitor chloroquine (CQ, 10 μM, 40 min) and immunoblot analysis was performed. ACTIN was used as loading control. For
LC3-II/ACTIN ratios band intensity ratios quantifications with the ImageJ software was used. (G and H) HEK293T expressing WT
or mutant (R93C and G157R) VCP/p97 were fractionated, and subcellular distribution of soluble (sol.) and insoluble (insol.)
proteins were analyzed by immunoblotting.
doi:10.1371/journal.pone.0164864.g007
P137L and G157C Mutant VCP/p97 Proteins Are Autophagy Targets
PLOS ONE | DOI:10.1371/journal.pone.0164864 October 21, 2016 13 / 19
We showed that, the P137L mutant interacted withWTVCP/p97 proteins (S4 Fig). Since the
mutant was unable to bind its cofactors and to contribute to VCP/p97-dependent cellular events
such as ER-associated protein degradation (ERAD), hexamers containing the mutant protein
should be non-functional. Indeed, upon expression of the P137L mutant, ubiquitylated protein
accumulation was increased in tunicamycin-treated cells suffering from ER stress(S5 Fig). More-
over, we have previously shown that mutant proteins causing ER stress and ERAD, namely
CFTRΔF508 and Tyrosinase C89R accumulated upon expression of the P137L mutant [17].
Binding of the p47 co-factor is important for VCP function in autophagic degradation. Yet,
the P137Lmutant was unable to bind this co-factor (probably due to a more detrimental alter-
ation of VCP structure in this mutant) and the protein formed non-functional aggregates. Under
these circumstances,mutant VCP/p97 proteins seemednot to interfere with the autophagy-
related function of the endogenous wild-typeVCP protein. Consequently, the wild-typeVCP
could still retain its function in autophagosome formation, and assist in the clearence of protein
aggregates by autophagy, including P137L mutant aggregates. Therefore, in the case of IBMPFD-
diseased individuals carrying the P137L mutation, WTVCP/p97 that is produced by the non-
mutated allele might still allow autophagic degradation to proceed in an efficientmanner.
In IBMPFD disease,P137Lmutant formed protein aggregates that did not prominently
interfere with autophagic degradation activity. But, ERAD functionwas still perturbedand ubi-
quitylated proteins accumulated (S5 Fig), resulting in the perturbation of normal cellular func-
tions [38]. In this context, preferential autophagic clearance of the mutant proteinallowedthe
enrichment of WT and functional VCP/p97 complexes (Fig 8). Therefore, autophagy activa-
tion in a subset of patients suffering from the IBMPFD diseasemight be beneficial and autop-
hagy-based treatment of these patients might be possible. Further studies will reveal whether
observationsmade here in in vitro cell culture conditions are valid in in vivo animal models.
Recently, VCP/p97 was shown to contribute to the autophagy of mitochondria (mitophagy)
[39, 40]. Yet in our system, expression of the P137L mutant did not prominently affect
Fig 8. Model of P137 mutant vs WT VCP/p97 degradation. Following autophagy stimulation by starvation
or Torin-1, aggregates containing VCP/p97 mutant P137L were sequestered in autophagosomes and
delivered to autolysosomes for degradation. A soluble fraction of the mutant protein could interact with WT
VCP/p97protein and form hetero-hexamers interfering with the function of the WT protein. On the other
hand, a major fraction of the WT VCP/p97was not colocalizing with autophagosomes and autolysosomes,
and it was not significantly degraded by the autolysosomal activity. Therefore, autophagy activation led to a
selective degradation of the mutant protein, while the WT counterpart was spared.
doi:10.1371/journal.pone.0164864.g008
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mitophagy compared toWTVCP/p97 under basal conditions, and even after treatment of cells
with the mitophagy inducer CCCP (S6 Fig). These results show that neither autophagy nor
mitophagy was defective in cells expressing the mutant protein.
VCP/p97 positive aggregates are not specific for IBMPFD. In a wide variety of diseases such
as Parkinson’s disease,Hungtinton’s disease, LewyBody disease, ALS and Machado-Joseph dis-
ease, VCP/p97 positive aggregates were observed [41–43]. Moreover, mutations of VCP/p97
were reported in a fraction of ALS patients [44]. Whether the P137L mutation and similar muta-
tions or conditions causing aggregation of the VCP/p97 protein contribute to the pathologies
observed in above-mentioned diseases is of interest. Large-scale genetic analysis of patients suf-
fering from IBMPFD and other more common diseases will reveal the frequency of such muta-
tions and the impact of the molecular events described in this study on disease progression.
Although all VCP/p97 mutations gave rise to clinical signs and symptoms of the IBMPFD
disease, we showed that molecular and cellular changes caused by different VCP/p97 mutants
(R155, R191, R93 mutants versus P137 and G157 mutants) were not identical. Our study
underlines the fact that caution should be exerted whenmodeling a disease based on single or
few commonmutations. Therefore, before designing a single common therapy approach for all
patients regardless of individual genetic changes, a better understanding of the biology of vari-
ous disease-associatedmutant proteins should be obtained.
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S1 Fig. VCP/p97 P137Lmutant induced both autophagosome and autolysosome formation
in U2OS and PC-12 cells. (A and C) Cells expressing empty vector wild type (WT), mutant
(P137L or R155C) VCP/p97 were co-transfectedwith RFP-GFP-LC3 fusion construct, treated
with chloroquine (CQ) for 40 min and dot formation was visualized in U2OS (A) and PC-12
(C) cells. Arrow heads indicate autophagosomes whereas arrows indicate autolysosomes. (A
and C) The graphs show the number of autophagosomes and autolysosomes in U2OS (B) and
PC-12 (D) cells under basal and chloroquine (CQ) treated condition. Data were shown as
mean ± SD of independent experiments (n = 3).  p<0.05,  p<0.01,  p<0.001.
(PDF)
S2 Fig. Mutant VCP/p97 formed aggregates and it was mainly found in the insoluble frac-
tion of cells. (A) HEK293T cells were transfected with wild type (WT) and mutant (P137L or
R155C) VCP/p97 and then analyzed under confocal microscopy. (B) Mouse primarymyoblast
cells were cotransfectedwith autophagosome marker GFP-LC3 and wild type (WT) or mutant
(P137L) VCP/p97 and analyzed using confocal microscopy under basal (NON-STV) or starved
(STV) conditions. (C-E) Cells expressingWT or mutant (P137L or R155C) VCP/p97 were
fractionated and subcellular distribution of proteins were analyzed by immunoblotting in
HEK293T (C), U2OS (D) or PC-12 (E) cells. Graphs show the percentage of the insoluble frac-
tion over total protein amount. ACTIN was used as loading control. (F) Wild type (WT) and
mutant P137L VCP/p97 expressing U2OS cells transfected with a GFP-p62 construct, and
association between p62 (Green) and VCP (Red) was analyzed under confocal microscopy.
(PDF)
S3 Fig. P137L mutant VCP/p97 is not a short-livedprotein. U2OS cells were transfected
with wild type (WT) or mutant (P137L) VCP/p97 in the absence or presence of 25 μM cyclo-
heximide (CHX) for indicated time points. Western blot analysis was performed by using
MYC and ACTIN antibodies. ACTIN was used as loading control. Image J software was used
for the quantification of band intensities.
(PDF)
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S4 Fig. P137L mutant can bind to WTVCP/p97. (A)MYC-tagged wild type (WT) or mutant
(P137L) were transfected to HEK293T cells. VCP proteins were precipitated using MYC-beads
and immunoblots were incubated with anti-MYC or anti-VCP/p97 antibodies. ACTIN was
used as loading control. (B) U2OS and (C) PC-12 cells expressing MYC-tagged wild type (WT)
or mutant (P137L) were co-transfectedwith GFP-tagged wild type VCP/p97. Myc-taggedWT
and P13L VCP proteins were immunoprecipitated using MYC-beads and blots were incubated
with GFP, VCP/p97 and ACTIN antibodies. ACTIN was used as oading control.
(PDF)
S5 Fig. P137L mutant expression led to ubiquitylated protein accumulation. (A)WT and
(B) P137L mutant VCP expressing cells were treated with 1 μg/ml Tunicamycin for indicated
time points (0 to 8 hours). An anti-ubiquitin antibody was used to detect ubiquitylated total
proteins. ACTIN was used as loading control.
(PDF)
S6 Fig. VCP/p97P137L mutant expression did not interfere withmitophagy. (A) HEK293T
cells expressing were co-transfectedwild type (WT) or mutant (P137L) VCP/p97 and autop-
hagymarker GFP-LC3 and mitochondrial marker Mito-dsRed. 10 μM CCCP treatment for 12
h was used as mitophagy inducer and DMSO as carrier. Mitophagy was assessed as
GFP-LC3-Mito-dsRed colocalization under confocal microscope. (B) Quantification of mito-
phagy positive cells (mean ± S.D. of independent experiments, n = 3. For each condition, 30
cells per point were counted.  p<0.01,  p<0.001, ns, not significant).
(PDF)
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